UNSPSC 51181922: Ganirelix

This classification denotes a gonadotropin releasing hormone inhibitor with the molecular formula C80H113ClN18O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IX503L9WN0, chemically known as d-alaninamide, n-acetyl-3-(1-naphthalenyl)-d-alanyl-4-chloro-d-phenylalanyl-3-(3-pyridinyl)-d-alanyl-l-seryl-l-tyrosyl-n6-(bis(ethylamino)methylene)-d-lysyl-l-leucyl-n6-(bis(ethylamino)methylene)-l-lysyl-l-prolyl- but generally known as ganirelix, which bears US NIH Compound Identifier 16130966.

UNSPSC 51181922 Ganirelix is a Commodity code representing pharmaceutical products supplied through state and local cooperative purchasing agreements. State and local governments procure ganirelix—a gonadotropin-releasing hormone antagonist used in fertility treatments—as part of broader multi-source pharmaceutical contracts that bundle generic drugs, branded pharmaceuticals, and over-the-counter products for distribution across state agencies, local health departments, school districts, and other public facilities. Procurement under this code typically flows through cooperative purchasing vehicles such as MMCAP (Minnesota Multistate Cooperative Purchasing Alliance) rather than individual agency direct buys, allowing multiple jurisdictions to leverage consolidated purchasing power and negotiate volume-based pricing with pharmaceutical manufacturers and authorized wholesalers.

The Minnesota Multistate Cooperative Purchasing Alliance, administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (S1070000015802) on January 20, 2026 with a response deadline of March 26, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating state and local government facilities, including Oregon. Vendors must demonstrate cGMP compliance and Drug Supply Chain Security Act certification, maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, or Morris & Dickson Co., LLC), and submit detailed product information including NDC codes, SKUs, UPCs, and manufacturing locations. Evaluation weights 75 percent on price competitiveness, 10 percent on fixed pricing for the contract term, and the remainder on administrative compliance, EDI capability, and administrative fee structure. The contract term runs two years for new responders with optional extensions, and all products must be available in the marketplace by May 15, 2026 with a minimum six-month shelf life.